



(51) International Patent Classification:

C07D 413/10 (2006.01) *A61K 31/5377* (2006.01)
C07D 261/04 (2006.01) *A61K 31/541* (2006.01)
A61K 31/42 (2006.01) *A61P 3/00* (2006.01)
A61K 31/454 (2006.01)

(21) International Application Number:

PCT/JP2015/000640

(22) International Filing Date:

12 February 2015 (12.02.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2014-025944 13 February 2014 (13.02.2014) JP

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(72) Inventors: **IKEDA, Zenichi**; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). **SASAKI, Minoru**; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). **KAKEGAWA, Keiko**; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). **KIKUCHI, Fumiaki**; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). **NISHIKAWA, Yoichi**; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 26-1,

Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP).

(74) Agents: **OHNO, Seiji** et al.; OHNO & PARTNERS, Marunouchi Kitaguchi Building 21F, 6-5, Marunouchi 1-chome, Chiyoda-ku, Tokyo, 1000005 (JP).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: HETEROCYCLIC COMPOUND



(57) Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.